All In Biotech

Drug Trial Radar · NCT06220123

A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Last checked: Nov 19, 2026Latest source record: Jul 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 225 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

225

Actual

Start

Feb 16, 2024

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Sponsor type
Industry
First posted
Jan 23, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.

Conditions

  • Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery

Interventions

  • SHR-2004Drug

    Investigational product arm: SHR-2004

  • Enoxaparin Sodium Injection; Rivaroxaban TabletsDrug

    Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Primary efficacy endpoint: The incidence rate of VTE from the first medication to the end of the treatment period (Day 28)Time frame: up to Day 28
  2. The composite endpoint incidence rate of major bleeding and clinically relevant non-major bleeding events as defined by the International Society on Thrombosis and Haemostasis (ISTH) from the first dose to the end of the treatment periodTime frame: up to Day 28

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Zhejiang Cancer Hospital

    Hangzhou, Zhejiang, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.